Skip to main content
. 2020 Nov;98(5):586–597. doi: 10.1124/molpharm.120.000047

Fig. 9.

Fig. 9.

Functional interactions between TRPA1 and TRPV3 activities. (A) Alterations in TRPA1-mediated calcium flux in lobar HBECs treated with AITC (150 μM) with or without the TRPA1 antagonist A967079 (20 μM) or the TRPV3 antagonist (TRPV3 Ant.; 10 μM). (B) Inhibition of TRPV3-mediated calcium flux in lobar HBECs treated with drofenine (250 μM) with or without the TRPA1 antagonist A967079 (20 μM) or a TRPV3 antagonist (10 μM). Data are presented as means ± S.E.M. from n ≥ 5 replicates. (C) Effects of the TRPA1 and TRPV3 antagonists on TRPA1-mediated calcium flux elicited byAITC (150 μM) in TRPA1-overexpressing HEK-293 cells (hTRPA1-OE HEK-293). (D) Effects of the TRPA1 and TRPV3 antagonists on TRPV3-mediated calcium flux by drofenine (250 μM) in TRPV3-overexpressing HEK-293 cells. Data are presented as means ± S.D. from n ≥ 3 replicates. *P < 0.05; **P < 0.01; using an ordinary one-way ANOVA with the Bonferroni correction.